Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 222

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 222
---
PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS (unaudited)

KEROS THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets 

(In thousands, except share and per share data) 

(Unaudited)

JUNE 30,2025DECEMBER 31,2024ASSETSCURRENT ASSETS:Cash and cash equivalents$690,215 $559,931 Accounts receivable 15,816 2,742 Prepaid expenses and other current assets26,777 26,220 Total current assets732,808 588,893 Operating lease right-of-use assets18,072 19,251 Property and equipment, net4,836 4,237 Restricted cash1,449 1,449 Other long-term assets— 2,056 TOTAL ASSETS$757,165 $615,886 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:Accounts payable$5,267 $4,602 Current portion of operating lease liabilities2,230 1,978 Accrued expenses and other current liabilities19,964 20,870 Deferred revenue925 — Current tax liability6,321 — Total current liabilities34,707 27,450 Operating lease liabilities, net of current portion15,724 16,883 Total liabilities50,431 44,333 STOCKHOLDERS' EQUITY:Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding— — Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding— — Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 40,615,414 and 40,554,705 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively4 4 Additional paid-in capital1,157,754 1,140,328 Accumulated